Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
BIOLOGICAL
2 trials
Sponsors
Livzon Pharmaceutical Group Inc.
Conditions
COVID-19 Pandemic
Phase 3
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study
Completed
NCT05096832
Livzon Pharmaceutical Group Inc.
COVID-19 Pandemic
Start: 2021-11-03
End: 2023-04-14
Updated: 2023-04-25
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III
NCT05096845
Livzon Pharmaceutical Group Inc.
COVID-19 Pandemic
Start: 2021-08-25
End: 2023-06-14
Target: 22500
Updated: 2023-04-25
Related Papers
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial
Emerging Microbes & Infections
2022-06-10
44 citations